ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

9475	Companies
185451	Keywords
117789	Articles
99301	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 07/01/2024 at 07:35, 1 year 5 months ago

OSE Immunotherapeutics Publishes Preclinical Efficacy Results for Lusvertikimab in ALL

Immunotherapy OSE Immunotherapeutics Preclinical Results Lusvertikimab Acute Lymphoblastic Leukemia
PRESS RELEASE

published on 07/01/2024 at 07:30, 1 year 5 months ago

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’
OSE Immunotherapeutics publie des résultats précliniques prometteurs sur Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans 'Blood', ouvrant de nouvelles perspectives en immunothérapie pour les patients atteints de LAL

Immunothérapie Publication OSE Immunotherapeutics Lusvertikimab Leucémie Aiguë Lymphoblastique
PRESS RELEASE

published on 07/01/2024 at 07:30, 1 year 5 months ago

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
OSE Immunotherapeutics announces publication of preclinical efficacy results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal 'Blood'. Collaboration with University Medical Center Schleswig-Holstein on targeting ALL patients

OSE Immunotherapeutics Lusvertikimab Acute Lymphoblastic Leukemia Blood Journal IL-7 Receptor Antagonist
BRIEF

published on 06/24/2024 at 07:35, 1 year 5 months ago

OSE Immunotherapeutics signs strategic agreement with MSK for CAR-T cell therapies

OSE Immunotherapeutics Leukemia Memorial Sloan Kettering Cancer Center CAR-T IL-7R
BRIEF

published on 06/24/2024 at 07:35, 1 year 5 months ago

OSE Immunotherapeutics signe un accord stratégique avec MSK pour les thérapies par cellules CAR-T

OSE Immunotherapeutics Leucémie Memorial Sloan Kettering Cancer Center CAR-T IL-7R
PRESS RELEASE

published on 06/24/2024 at 07:30, 1 year 5 months ago

OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T
OSE Immunotherapeutics annonce un accord avec le Memorial Sloan Kettering Cancer Center pour les thérapies CAR-T. L'accord porte sur des brevets dans le traitement des cancers exprimant l'IL-7R

Brevets OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center IL-7R Thérapies CAR-T
PRESS RELEASE

published on 06/24/2024 at 07:30, 1 year 5 months ago

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
OSE Immunotherapeutics partners with Memorial Sloan Kettering Cancer Center for CAR T-cell therapy agreement. MSK to lead development and share revenues with OSE

Agreement CAR T-cell Therapy OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center Revenue Sharing
BRIEF

published on 06/20/2024 at 07:35, 1 year 5 months ago

OSE Immunotherapeutics presents promising data on the mRNA platform at the FOCIS congress

Autoimmune Diseases OSE Immunotherapeutics FOCIS 2024 IL-35 Therapeutic MRNA
BRIEF

published on 06/20/2024 at 07:35, 1 year 5 months ago

OSE Immunotherapeutics présente des données prometteuses sur la plateforme ARNm au congrès FOCIS

Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique FOCIS 2024 IL-35
PRESS RELEASE

published on 06/20/2024 at 07:30, 1 year 5 months ago

OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)
OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique au congrès annuel FOCIS à San Francisco. L'IL-35 joue un rôle clé dans le contrôle des maladies auto-immunes et inflammatoires

Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique IL-35 FOCIS

Accesswire

Published on 12/05/2025 at 02:35, 9 hours 40 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 9 hours 45 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 11 hours 15 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 13 hours 10 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 13 hours 15 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 12:05, 10 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 15 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 15 minutes ago

Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million
Published on 12/05/2025 at 11:14, 1 hour ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 11:08, 1 hour 6 minutes ago

Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

Les Echos

Published on 12/05/2025 at 08:45, 3 hours 30 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 3 hours 30 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 3 hours 32 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 18 hours ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 18 hours 15 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE